Refine your search
Collections
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Neelam, Prajapati
- Pharmacology of Combined Mesalazine and Rifaximin Therapy to Inflammatory Bowel Disease
Abstract Views :167 |
PDF Views:2
Authors
Affiliations
1 Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, IN
1 Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, IN
Source
Asian Journal of Pharmacy and Technology, Vol 6, No 1 (2016), Pagination: 45-50Abstract
This review article presents the pharmacology of combined Mesalazine and Rifaximin therapy especially in inflammatory bowel disease. Mesalazine is as used in anti-inflammatory agent, Non-Steroidal. Rifaximin is used in Gastrointestinal Agents, Anti-infective agent. The use of Rifaximin in combination with Mesalazine has been proved to provide beneficial effect in inflammatory bowel disease. The mechanism of Mesalazine and Rifaximin is quite different. Mesalamine and Rifaximin are two different types of drugs offering some symptomatic relief to the IBD patients. Mesalamine treats inflammation, whereas, Rifaximin reduces bio burden. Patent for combination of both drugs were approved by WIPO. The main objective of this review article is to provide pharmacological information of combined therapy of Mesalazine and Rifaximin to researcher in development of combined dosage form of this.Keywords
Mesalazine, Rifaximin, Inflammatory Bowel Disease, Pharmacology.- Combined Treatment of Aripiprazole and Escitalopram Oxalate Therapy to Treat Major Depressive Disorders
Abstract Views :188 |
PDF Views:2
Authors
Affiliations
1 Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, IN
1 Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, IN
Source
Asian Journal of Research in Pharmaceutical Sciences, Vol 6, No 2 (2016), Pagination: 113-115Abstract
This review article presents the pharmacology of combined treatment of Aripiprazole and Escitalopram oxalate in treatment of Major Depressive Disorders. Aripiprazole is anti psychotic agent. Escitalopram Oxalate is also an antidepressant agent (Selective Serotonin Reuptake Inhibitor). Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia. Escitalopram Oxalate is selective serotonin reuptake inhibitors (SSRIs) are a group of chemically diverse antidepressant drugs that specifically inhibit serotonin reuptake. The SSRIs block the reuptake of serotonin, leading to increased concentrations of the neurotransmitter in the synaptic cleft and, ultimately, to greater postsynaptic neuronal activity. The combination of both have decrease dose and improve Depression. Combination of both the drugs were approved by us government and has been used in Major Depressive Disorders. The main objective of this review article is to provide pharmacological information of combined therapy of of Aripiprazole and Escitalopram Oxalate to researcher in development of combined dosage form of this.Keywords
Aripiprazole, Escitalopram Oxalate, Major Depressive Disorders, Pharmacology.- Pharmacology of Combined Treatment of Saxagliptin Hydrochloride and Glibenclamide Therapy to Treat Type-2 Diabetes
Abstract Views :162 |
PDF Views:2
Authors
Affiliations
1 Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist. Surat, Gujarat, IN
1 Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist. Surat, Gujarat, IN